Lifecore Biomedical - Public Comps and Valuation Multiples

Lifecore Biomedical Overview

About Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Founded

1986

HQ

Employees

406

Website

lifecore.com

Sectors

Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $130M

LTM EBITDA $20.1M

EV

$404M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Lifecore Biomedical Financials

As of August 2025, Lifecore Biomedical reported last 12-month revenue of $130M and EBITDA of $20.1M.

In the same period, Lifecore Biomedical generated $40.9M in LTM gross profit and -$35.3M in net income.

See Lifecore Biomedical valuation multiples based on analyst estimates

Lifecore Biomedical P&L

In the most recent fiscal year, Lifecore Biomedical reported revenue of $129M and EBITDA of -$8.8M.

Lifecore Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Lifecore Biomedical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$130M	XXX	$129M	XXX	XXX	XXX
Gross Profit	$40.9M	XXX	$40.3M	XXX	XXX	XXX
Gross Margin	32%	XXX	31%	XXX	XXX	XXX
EBITDA	$20.1M	XXX	-$8.8M	XXX	XXX	XXX
EBITDA Margin	16%	XXX	-7%	XXX	XXX	XXX
EBIT	-$5.4M	XXX	-$12.0M	XXX	XXX	XXX
EBIT Margin	-4%	XXX	-9%	XXX	XXX	XXX
Net Profit	-$35.3M	XXX	-$38.7M	XXX	XXX	XXX
Net Margin	-27%	XXX	-30%	XXX	XXX	XXX
Net Debt	XXX	XXX	$122M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Lifecore Biomedical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $130M. EBITDA for the last twelve months was $20.1M. In the most recent fiscal year, Lifecore Biomedical achieved $129M in revenue and -$8.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$130M	Analyst estimates available to subscribers	$129M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$40.9M	Analyst estimates available to subscribers	$40.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	31.5% gross margin	Analyst estimates available to subscribers	31.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$20.1M	Analyst estimates available to subscribers	-$8.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	15.5% EBITDA margin	Analyst estimates available to subscribers	-6.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$5.4M	Analyst estimates available to subscribers	-$12.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-4.1% EBIT margin	Analyst estimates available to subscribers	-9.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$35.3M	Analyst estimates available to subscribers	-$38.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-27.2% net profit margin	Analyst estimates available to subscribers	-30.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$122M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Lifecore Biomedical

This financial data table provides comprehensive performance metrics for Lifecore Biomedical, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Lifecore Biomedical generated $130M in revenue over the last twelve months.
The company achieved $20.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $40.9M.
Net income over the last twelve months reached -$35.3M.

Fiscal Year Performance

In the most recent fiscal year, Lifecore Biomedical reported $129M in total revenue.
Fiscal year EBITDA was -$8.8M.
The company maintained a gross profit margin of 31.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was -6.8%.
Net profit margin reached -30.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Lifecore Biomedical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Lifecore Biomedical Stock Performance

Lifecore Biomedical has current market cap of $281M, and EV of $404M.

Market Cap Evolution

Lifecore Biomedical Stock Data

As of September 12, 2025, Lifecore Biomedical's stock price is $8.

See Lifecore Biomedical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$404M	$281M	XXX	XXX	XXX	XXX	$-1.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Lifecore Biomedical Valuation Multiples

Lifecore Biomedical's trades at 3.1x EV/Revenue multiple, and -45.8x EV/EBITDA.

See valuation multiples for Lifecore Biomedical and 15K+ public comps

Lifecore Biomedical Financial Valuation Multiples

As of September 12, 2025, Lifecore Biomedical has market cap of $281M and EV of $404M.

Equity research analysts estimate Lifecore Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lifecore Biomedical has a P/E ratio of -8.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$281M	XXX	$281M	XXX	XXX	XXX
EV (current)	$404M	XXX	$404M	XXX	XXX	XXX
EV/Revenue	3.1x	XXX	3.1x	XXX	XXX	XXX
EV/EBITDA	20.1x	XXX	-45.8x	XXX	XXX	XXX
EV/EBIT	-74.9x	XXX	-33.6x	XXX	XXX	XXX
EV/Gross Profit	9.9x	XXX	n/a	XXX	XXX	XXX
P/E	-8.0x	XXX	-7.3x	XXX	XXX	XXX
EV/FCF	-29.7x	XXX	-29.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Lifecore Biomedical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Lifecore Biomedical Margins & Growth Rates

Lifecore Biomedical's last 12 month revenue growth is 9%

Lifecore Biomedical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Lifecore Biomedical's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lifecore Biomedical's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Lifecore Biomedical and other 15K+ public comps

Lifecore Biomedical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	9%	XXX	6%	XXX	XXX	XXX
EBITDA Margin	16%	XXX	-7%	XXX	XXX	XXX
EBITDA Growth	33%	XXX	-23%	XXX	XXX	XXX
Rule of 40	38%	XXX	2%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	38%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	41%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial